PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
L.G. Zangani, LLC
 

Company Overview

Contact Info & Offices

Press Releases

L.G. Zangani, LLC

Press Release


Receive press releases from L.G. Zangani, LLC: By Email RSS Feeds:

Zangani Investor Community Announces ViRexx's OvaRex® MAb Coverage


In an effort to better educate the community at www.zangani.com; two new articles have been posted. One is an in-depth blog written by stockinterview.com. The second is an easy-to-understand video/podcast that shows how Ovarex® MAb is used to trigger the body’s immune system to respond to ovarian cancer.

Flemington, NJ, April 01, 2006 --(PR.com)-- The Zangani Investor Community announced today two new pieces on Ovarex® MAb in an effort to better educate the community on the value of ViRexx's lead anti-tumor product. The two new articles include an in-depth blog written by stockinterview.com
(http://www.zangani.com/virexx/2006-0331-rex-blog),
the second is an easy-to-understand video/podcast
(http://www.zangani.com/virexx/2006-0331-rex)
that shows how Ovarex® MAb is used to trigger the bodies immune system to respond to ovarian cancer.

The value in these two pieces shows how invaluable the tools and resources built at www.zangani.com are enlightening prospective investors in exciting and new companies. Making use of the latest web technologies to profile and expose a great story. Video can be seen online or automatically downloaded to ones’ ipod for later viewer, and the blog is in a RSS format that can be aggregated and/or download to an RSS reader.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.

ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.

About Zangani
Zangani is an outsourced IR and Business Development firm specializing in small cap and micro cap companies. They provide clients with an array of investor relations products, including customized company strategies, community forums, and webcasting which are tailored for small cap budgets. For more information please visit their website at http://www.zangani.com

Note: Except for the historical information contained herein, this press release contains, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such statement may include, without limitation, statements with respect to the Company’s plans, objectives, expectations and intentions and other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).

L.G. Zangani, LLC provides financial public relations service to the Company. As such L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and or other services in the form of monies, capital stock in the Company, warrants or options to purchase capital in the Company. The full disclaimer can be read here at http://www.zangani.com/disclaimer.

Contact:
Kevin Nally
Zangani Investor Community
9 Main Street
Flemington, NJ 08822
office@zangani.com
http://www.zangani.com

###
Contact Information
L.G. Zangani, LLC
Kevin Nally
908-788-9660
Contact
www.zangani.com
X 625

Click here to view the company profile of L.G. Zangani, LLC
Click here to view the list of recent Press Releases from L.G. Zangani, LLC
Promote Your Business